Minimally Invasive Aesthetic Treatment of the Face and Neck Using Combinations of a PCL-Based Collagen Stimulator, PLLA/PLGA Suspension Sutures, and Cross-Linked Hyaluronic Acid
Received 4 February 2020
Accepted for publication 9 April 2020
Published 5 May 2020 Volume 2020:13 Pages 333—344
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Francisco de Melo,1 Alieksiéi Carrijo,2 Kyungkook Hong,3 Bruno Trumbic,4 Franco Vercesi,5 Heidi A Waldorf,6 Sabine Zenker7
1Aesthetics International, Dubai, United Arab Emirates; 2Clínica Carrijo, São Paulo, Brazil; 3Hus-hu Dermatology Clinic, Seoul, South Korea; 4Cap Evidence, Paris, France; 5Aesthetic Surgery and Laser, Milan, Italy; 6Waldorf Dermatology Aesthetics, Nanuet, NY, USA; 7Dr Zenker Dermatology, Munich, Germany
Correspondence: Francisco de Melo Tel +971 56 175 3929
Background: Combinations of minimally invasive procedures (MIPs) are often used in aesthetic treatments and are increasingly considered as the new standard of care. Three agents with specific properties are available in this perspective: a polycaprolactone (PCL)-based collagen stimulator, a poly-L-lactic acid (PLLA)- and a poly-glycolic acid (PLGA)-based resorbable suspension suture with a 3D-cone technology, and a cross-linked hyaluronic acid (HA).
Objective: To develop the first practice guidelines on rejuvenation treatment of the face and the neck using combinations of these agents, whether associated or not with other widely used MIPs such as botulinum neurotoxins or energy-based devices.
Methods: A multi-disciplinary, multi-national board of plastic surgeons and dermatologists convened to develop guidelines using a predefined consensus method. The consensus was defined as ≥ 83% agreement rate between participants.
Results: Practice guidelines and algorithms, describing optimal procedure sequence and spacing, are proposed for the treatment of upper-, mid-, lower-face and neck, combining the PCL collagen stimulator, the PLLA/PLGA suspension sutures, and the cross-linked HA, whether associated or not with other MIPs.
Conclusion: These new guidelines provide general support to optimal management strategies. Individual treatment plans should be adapted according to the physician’s individual competence and the patient’s preferences.
Keywords: botulinum toxins, combined modality therapy, dermal fillers, energy-based device, practice guideline, rejuvenation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]